List view / Grid view
8 May 2017 | By Niamh Marriott, Junior Editor
Braeburn Pharmaceuticals’ 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia...
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Administration of Adasuve results in rapid absorption of loxapine, with a maximum plasma concentration achieved in approximately 2 minutes...
1 June 2016 | By Victoria White, Digital Content Producer
The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients...
5 April 2016 | By Victoria White
If approved, this 3‑monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations...
14 March 2016 | By Victoria White
The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia...
10 February 2016 | By Victoria White
HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...
7 October 2015 | By Victoria White
Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...
24 June 2015 | By Victoria White
Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)...
9 June 2015 | By Victoria White
Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project - Open Translational Science in Schizophrenia...
6 May 2015 | By Victoria White
Indivior has announced top-line results from its Phase 3 clinical trial of RBP-7000, an investigational drug for the treatment of schizophrenia...
3 February 2015 | By Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial…
11 November 2014 | By Janssen
Compared with their peers and other caregivers, carers for adults with schizophrenia report deteriorated physical and mental health and greater health resource usage/utilisation...
23 December 2013 | By Lundbeck
New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations...
21 September 2013 | By
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation for the maintenance treatment of schizophrenia in adult patients stabilised…
7 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…
